Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,310 public trials 520 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Active, Not Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, Not Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +30 more
Locations
  • The University of Chicago Medical Center - Hyde Park - Hematology & Oncology Chicago, Illinois, United States
  • UNC Hospitals - UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • START | San Antonio San Antonio, Texas, United States
  • South Texas Accelerated Research Therapeutics | START Rocky Mountain Region West Valley City, Utah, United States
View all 26 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • Jewish General Hospital Montreal, Quebec, Canada
  • Seoul National University Hospital Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
View all 15 locations
View Trial Details
Active, Not Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The Oncology Institute (TOI) Clinical Research Cerritos, California, United States
  • Norton Cancer Institute, St. Matthews Louisville, Kentucky, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Chiba University Hospital Chiba, Japan
  • Kyushu University Hospital Fukuoka, Japan
  • Hokkaido University Hospital Hokkaido, Japan
  • Kyoto University Hospital Kyoto, Japan
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05156281

Conditions
Charcot-Marie-Tooth disease, Type 1F, Disease Attributes, Pathologic Processes, +3 more
Locations
  • Ctr for Neurology and Spine Phoenix, Arizona, United States
  • Vladimir Royter MD APMC Hanford, California, United States
  • VA Greater LA Healthcare System Los Angeles, California, United States
  • Regina Berkovich MD PhD Inc West Hollywood, California, United States
View all 222 locations
View Trial Details
Active, Not Recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Brain Diseases, +59 more
Locations
  • University of California San Diego La Jolla, California, United States
  • UCSF Benioff Children's Hospital San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Egleston Children's Hospital at Emory University Atlanta Atlanta, Georgia, United States
View all 26 locations
View Trial Details

Related conditions